China Pharma Holdings (CPHI) Other Non-Current Liabilities (2010 - 2023)

China Pharma Holdings (CPHI) has 10 years of Other Non-Current Liabilities data on file, last reported at $2.2 million in Q1 2023.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $2.2 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $2.2 million (changed N/A YoY) and the FY2022 annual result came in at $2.4 million, up 26.85% from the prior year.
• Other Non-Current Liabilities slipped to $2.2 million in Q1 2023, from $2.4 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $3.1 million in Q2 2021 to a low of $1.7 million in Q3 2021.
• A 5-year average of $2.3 million and a median of $2.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities slumped 31.44% — and 2022, when it gained 26.85%.
• Tracing CPHI's Other Non-Current Liabilities over 5 years: stood at $2.4 million in 2019, then increased by 14.44% to $2.7 million in 2020, then tumbled by 31.44% to $1.9 million in 2021, then advanced by 26.85% to $2.4 million in 2022, then declined by 9.15% to $2.2 million in 2023.
• The last three Other Non-Current Liabilities figures came in at $2.2 million (Q1 2023), $2.4 million (Q4 2022), and $1.9 million (Q4 2021), per Business Quant data.